<a id="bm-comp-45de29d7-eeb3-481c-af3f-4dbcf10c973f" name="bm-comp-45de29d7-eeb3-481c-af3f-4dbcf10c973f" class="BMCustomAnchor"></a><table><tr><td bm-component-id="45de29d7-eeb3-481c-af3f-4dbcf10c973f" style="vertical-align: top; width:100.000000%;"><ul><li><font color="#000000">Financials fairly in line</font></li><li><font color="#1B2634"><font color="#000000">Entering the final stage of Phase 1b, Phase 2 expected by YE'26</font></font></li><li><font color="#000000">Fairly neutral share price reaction expected</font></li></ul></td></tr></table><a id="bm-comp-2d97dafe-195e-4fec-852a-b8bf00398ed4" name="bm-comp-2d97dafe-195e-4fec-852a-b8bf00398ed4" class="BMCustomAnchor"></a><table><tr><td bm-component-id="2d97dafe-195e-4fec-852a-b8bf00398ed4" style="vertical-align: top; width:100.000000%;"><h3 class="bm-h3" style="text-align:left;"><font color="#000000">Financials fairly in line</font></h3><p style="text-align:left;"><font color="#000000">For Q2'26, net income was in line with expectations at SEK -16m (vs. ABGSCe at SEX -15m and SEK -15m in Q1'<font color="#000000">26) as</font> opex remained well controlled, with a slight beat on CF from operating activities at SEK -14m (vs. ABGSCe at SEK -15m and SEK -16m in Q1'26). Cash and cash equivalents came in at SEK 115m (SEK 111m in Q1'<font color="#000000">26),</font> as the ~SEK 18m in net proceeds from the TO1 warrant exercise received in the quarter more than offset the operating cash burn.</font> <font color="#000000">Together with proceeds from the TO2 warrants due in November 2026, we continue to estimate a financial runway into 2028e.</font></p><h3 class="bm-h3" style="text-align:left;"><font color="#1B2634"><font color="#000000">Entering the final stage of Phase 1b</font></font></h3><p style="text-align:left;"><font color="#000000">During the quarter, Isofol continued to advance the Phase 1b dose-escalation part of its ongoing Phase 1b/2 trial of arfolitixorin in metastatic colorectal cancer, successfully evaluating the third dose cohort at 300 mg/m² without dose-limiting toxicities and maintaining a consistently favourable safety profile across all three dose levels tested to date (120, 200 and 300 mg/m²). In April, the company also received BfArM approval for an optimise<font color="#000000">d study design, including broader Phase 2 inclusion criteria, a direct comparison with leucovorin (</font>the standard folate component of current 5-FU-based chemotherapy regimens), and the addition of further study centres to address slower-than-expected recruitment. After the quarter, Isofol opened the fourth and highest dose cohort at 500 mg/m² in July <font color="#000000">following safety committee approval, moving directly to this dose based on the favourable safety data from the preceding cohorts.</font> Yesterday, the company reiterated that it still expects to enter Phase 2 before year-end and noted that two new university hospitals in Germany have been added to strengthen study execution and recruitment. Phase 2 is planned to involve 10-15 hospitals across several European countries, alongside parallel patient recruitment in Japan through partner Solasia Pharma’s bridging trial.</font></p><h3 class="bm-h3" style="text-align:left;"><font color="#1B2634"><font color="#000000">Fairly neutral</font> share price reaction expected</font></h3><p style="text-align:left;"><font color="#212529"><font color="#000000">As expec<font color="#000000">ted, there was rather limited incremental news in the report, which combined with the opex in line, leads us to expect</font></font></font> <font color="#000000">no significant estimate revisions and a fairly neutral to small negative share price reaction today. As usual, there will not be hosted a webcast today.</font></p></td></tr></table>